ICIs for NSCLC: Patients With ILD Show Greater Risk ICIs for NSCLC: Patients With ILD Show Greater Risk
Immune checkpoint inhibitors can be effective in patients with non-small cell lung cancer and mild interstitial lung disease, but with a greater risk.Medscape Medical News
Source: Medscape Pathology Headlines - Category: Pathology Tags: Pulmonary Medicine News Source Type: news
More News: Cancer | Cancer & Oncology | Interstitial Lung Disease | Lung Cancer | Non-Small Cell Lung Cancer | Pathology